Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Effects of Liraglutide on Glycemic Control
Studying patients with T2D and multiple injections
Patients with type 2 diabetes can benefit from adding liraglutide to their multiple daily insulin injections through improved glycemic control without an increased risk of hypoglycemia, reduction in body weight, and the ability to lower insulin doses, according to a study of 124 participants who were randomized 1:1 to subcutaneous liraglutide or placebo. Researchers found:
• Liraglutide was associated with a significant reduction in HbA1c vs placebo (1.5% vs 0.4%, respectively).
• Body weight was significantly reduced in patients in the liraglutide group vs the placebo group and total daily inulin doses were also significantly reduced.
• Glycemic variability was reduced in patients treated with liraglutide.
Citation: Lind M, Hirsch IB, Tuomilehto J, et al. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomized clinical trial (MDI Liraglutide trial). BMJ. 2015;351:h5364. doi:10.1136/bmj.h5364.
1.) Rosenstock J, Fonseca VA, Gross JL, et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care 2014;37(8):2317-2325. doi:10.2337/dc14-0001.
This Week's Must Reads
Must Reads in Obesity
Physical Activity & Incidence of CHD & CVD in Women, JAMA Netw Open; ePub 2019 Mar 15; LaCroix, et al
Coffee Consumption & Plasma Biomarkers, Am J Clin Nutr; ePub 2019 Mar 5; Hang, et al
Fitness & BMI in Adolescence Tied to Adult Disability, Ann Intern Med; ePub 2019 Feb 12; Henriksson, et al
BMI Measurements and Intensive BP Management , Am J Med; ePub 2019 Feb 2; Oxlund, et al